TR64 for advanced solid tumors that standard treatment failed
Part of Cancer clinical trials.
This early-phase trial studies TR64 in people with advanced solid cancers when standard treatments have stopped working or aren’t an option. It aims to see whether the drug can reduce tumors and is safe enough to keep studying.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign consent and be willing to follow all study instructions.
- You must be 18 or older (when you sign).
- You must have advanced solid cancer confirmed by biopsy or other lab testing, and it must be that standard treatment failed, isn’t available, or doesn’t fit for you.
- You must have measurable tumors that can be tracked on scans.
- Your overall health score (ECOG) must be 0 to 2, meaning you’re not too limited in daily activities.
- Your blood tests and organ function must be within certain limits (for example, white blood cells, platelets, liver tests, and kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (TGRX-1942) for people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and see how well the drug works.
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
This is an early-stage study testing a new drug called GTB-5550 in people with advanced cancers that have spread. The study aims to find the right dose and see if the drug helps shrink tumors.
This trial tests a new investigational drug, TORL-4-500, for people with advanced solid tumors that have not responded to other treatments. It aims to find a safe dose and see if the drug can help shrink or control the cancer.
This trial tests a new drug called TQB6426 for people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called GPC3 found on some tumors, aiming to deliver a powerful therapy directly to the cancer cells.
This trial tests a new drug, TQB6411, for people with advanced cancers that have not responded to standard treatments. It aims to see if the drug is safe and effective for different tumor types.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.